Donnagel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Donnagel

Quick Facts

Property Description
Active Ingredients Kaolin, Pectin, Belladonna Alkaloids
Form Oral Suspension or Liquid
Pharmacological Class Adsorbent / Anticholinergic Combination
Common Use Symptomatic relief of acute diarrhea and cramping
Origin Mineral and Plant-Derived

What is Donnagel?

What Type of Medicine is Donnagel?

Donnagel is a combination medication classified as an oral antidiarrheal agent used to relieve the symptoms of acute, non-specific diarrhea. The formulation is typically presented as a liquid oral suspension, making it easily ingested. Its dual function places it within the pharmacological classes of both adsorbents and anticholinergics, offering a comprehensive approach to managing digestive upset.

The combination of kaolin and pectin is used for stool consolidation, utilizing adsorbent properties to help firm up loose stools.


What are the Active Ingredients in Donnagel?

The distinguishing active components in Donnagel are the mineral-based adsorbent Kaolin, the carbohydrate Pectin, and a mixture of naturally sourced Belladonna Alkaloids. Kaolin and Pectin work together to absorb excess water and bind irritants in the bowel. The inclusion of the alkaloids (such as Hyoscyamine and Atropine) provides the medicine's anticholinergic properties.

Belladonna Alkaloids are plant-derived substances that act to relax the smooth muscles of the stomach and intestines. This feature is intended to help ease the cramping and spasms often associated with diarrhea.


What is Donnagel Used For?

Donnagel is primarily used for providing symptomatic relief from the effects of acute, simple diarrhea, including associated abdominal cramping and spasms. It is intended for short-term, temporary management to lessen the frequency of loose stools and improve stool consistency during mild episodes of digestive upset.

Its purpose is to address symptoms rather than the underlying cause of infection or illness. The medicine is utilized to help calm the gut and reduce the watery content of stools.

Regulatory References

  1. NIH DailyMed Drug Information

What side effects are possible with Donnagel?

Possible Side Effects and Safety Information

The officially documented safety profile for Donnagel, which includes Belladonna Alkaloids, is defined by adverse reactions primarily related to the medicine's anticholinergic effects, as recognized in authoritative government regulatory documents.


Frequency and System-Organ Effects

Adverse reactions are classified according to frequency and impact on various body systems. Common side effects generally involve the Gastrointestinal (constipation, dry mouth, bloating) and Nervous Systems (dizziness, drowsiness, weakness, headache). Other common effects include Ocular (blurred vision) and Skin disorders (decreased sweating, dry skin).

System-Organ Class Common Adverse Reactions
Gastrointestinal Constipation, dry mouth, bloating
Nervous System Dizziness, drowsiness, weakness
Ocular Blurred vision
Skin Decreased sweating, dry skin

Serious Adverse Reactions and Safety Constraints

Official regulatory labeling documents the potential for serious adverse reactions, although these are rare. These include severe allergic responses, significant Central Nervous System effects (e.g., severe confusion, hallucinations), and marked Cardiac events such as tachycardia. Diarrhea may be an early sign of an incomplete intestinal obstruction, requiring attention.

Population-Specific Considerations are noted for increased sensitivity in certain groups. Older adults are more susceptible to anticholinergic effects like confusion and urinary difficulty. Pediatric patients have a noted risk of severe side effects and rapid body temperature increase due to impaired sweating, which restricts the body's ability to regulate heat in warm environments or during exercise.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile of Donnagel is characterized by the effects of the Belladonna Alkaloids component, which may lead to documented anticholinergic toxicity. Officially recognized clinical manifestations of overdose include widespread systemic and neurological signs such as blurred vision, dilated pupils (mydriasis), profound dryness of the mouth, difficulty swallowing, and hot and dry skin. Patients may also experience headache, nausea, and evidence of CNS stimulation or dizziness.

The potential for severe systemic and neurological outcomes, including a theoretical curare-like action, is noted in regulatory warnings. These risks mandate that immediate medical attention be sought upon the appearance of any overdose manifestations.

Emergency management requires hospital monitoring and specific procedural interventions. Documented measures for supportive treatment include gastric lavage, administration of activated charcoal, and the potential use of parenteral cholinergic agents when indicated, which serve as an antidote. Management is focused on symptomatic and supportive care.

Special consideration is officially noted for certain patient populations. Children are documented as being more sensitive to these effects, with risks of unusual excitement and rapid increases in body temperature (hyperthermia). Elderly patients are more susceptible to central effects, including confusion and agitation.

Therapeutic Uses of Donnagel

What Donnagel Treats: Main Uses and Benefits

Easing Discomfort from Abdominal Cramping and Spasms

This medicine is commonly used in situations involving symptomatic discomfort arising from symptoms of increased neurological or muscular activity, a common feature of acute digestive upset. The combination is applied when supportive symptom management is appropriate. It helps address symptom clusters such as painful cramping and spasms that may appear suddenly, offering supportive relief to ease the overall burden of these muscle contractions and contributes to improved comfort during periods of heightened symptoms.

The medication is commonly used to help with acute diarrhea, abdominal cramping, and intestinal spasms.

“It is relevant across domains where short-term symptom management is appropriate.”


Providing Support for Loose Stool Frequency and Consistency

Donnagel is relevant across conditions characterized by episodic or fluctuating symptom patterns involving the bowel. It is applied when symptoms cluster into patterns of frequent, loose, or watery stools, helping to address the disruptive symptom manifestations. This provides symptomatic relief that assists with maintaining functional stability and helps patients cope more steadily with difficult episodes.

Quick Fact: Supports management of Acute Symptomatic Diarrhea

Regulatory References

  1. NIH MedlinePlus overview of anticholinergic combinations

Eligibility and Restrictions for Use

Eligibility Scope

Classification Population/Condition
Use Allowed Adults and Teenagers (under standard labeled conditions). Children 2 to 12 years of age (permitted use).
Not Recommended Children up to 2 years of age (Infants) due to increased susceptibility to effects of Belladonna Alkaloids.
Contraindicated Glaucoma, obstructive uropathy, obstructive gastrointestinal disease (including paralytic ileus), or known hypersensitivity to any ingredient. Use is also contraindicated in patients with severe ulcerative colitis or unstable cardiovascular status in acute hemorrhage.

Age- and Condition-Based Restrictions

Category Regulatory Statement
Geriatric Use Must be used with caution; older adults are typically more sensitive to anticholinergic effects.
Organ Function Caution is required in patients with hepatic (liver) disease or renal (kidney) disease.
Pregnancy Status Classified as Category C. Should be administered only if clearly needed.
Lactation Status Caution should be exercised; it is unknown if the drug is excreted in human milk, and it may suppress milk production.

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Donnagel by establishing non-eligibility through formal contraindications that primarily relate to the product's anticholinergic component, excluding patients with specific obstructive diseases or glaucoma. Eligibility for remaining populations is then subjected to restrictions and caution for age groups (infants and older adults) and specific conditions (renal or hepatic impairment) to mitigate potential risks associated with drug sensitivity or elimination.

What should I know about interactions with other medicines?

Donnagel contains attapulgite, an adsorbent material that can interact with other oral medicines. Its primary mechanism is to physically bind to and reduce the absorption of drugs in the stomach and intestines. This may lead to reduced effectiveness of the co-administered drug.

Documented Drug Interactions

Official documents classify known drug interactions into three categories of clinical significance:

Classification Clinical Significance Recommended Action
Major Highly clinically significant Avoid combination; the risk outweighs the benefit.
Moderate Moderately clinically significant Usually avoid combination; use only under special circumstances.
Minor Minimally clinically significant Minimize risk; consider an alternative or monitoring.

It is documented that attapulgite has a known interaction profile with over 70 different medications, including major, moderate, and minor classifications. This wide range of interactions reflects the adsorbent nature of the ingredient.

Interaction Management

To minimize the risk of interaction, it is generally recommended to separate the administration of Donnagel from any other oral medication by two to three hours. This time separation allows the other medicine to be absorbed before the adsorbing agent is introduced. Always consult a healthcare professional for specific advice on spacing medications.

Mechanism of Action

The mechanism of action for Donnagel, whose active ingredient is the clay mineral attapulgite, is primarily confined to the intestinal lumen and involves two distinct physical actions. The first is Gastrointestinal Toxin and Water Adsorption. Attapulgite acts as a high-surface-area intestinal adsorbent. The main targets are the contents within the lumen, where the compound physically binds to and immobilizes large quantities of free water, as well as various soluble and insoluble toxins and bacteria. This non-systemic engagement results in the reduction of free luminal fluid volume and the immobilization of irritants. The system-level physiological consequence is a decrease in luminal viscosity and frequency of intestinal transit. The second action is Physiological Barrier Modulation. Attapulgite forms a uniform, non-adherent layer along the mucosal lining. This physical layer alters the interaction between the luminal contents and the mucosal surface by separating the surface from local irritants and mediators that might otherwise stimulate excessive motility or secretion. This reduces the accessibility of mediators to the intestinal wall, modulating downstream signaling patterns.

Dosage and Administration Information

Administration Methods

Donnagel is typically administered orally. When using the liquid suspension form, the medication requires thorough shaking of the bottle before each use to ensure the active ingredients are evenly distributed. For precise measurement, a standardized medication cup or measuring spoon is utilized rather than a household spoon, as household items may not provide an accurate volume.

Timing and Food Intake

This medication is generally taken at the first sign of symptoms. It can be taken with or without food, depending on individual preference or specific gastrointestinal comfort. Maintaining adequate hydration with water or oral rehydration solutions is often suggested while using this product to support overall recovery.

Storage and Handling

The product should be stored at room temperature, away from direct light and moisture. The cap should be kept tightly closed when the medication is not in use. It is important to keep the container out of reach of children and pets to prevent accidental ingestion.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Initial Trials

Initial research focused on the compound's potential effects on the PX receptor pathway. Studies assessed whether short-term use of the compound was followed by changes in biomarker B1 levels in a healthy, controlled population.

  • Phase I (Safety and Pharmacokinetics): Safety profiles were evaluated across various study populations by researchers. Key goals were to establish the rate of absorption and metabolism. The research reported gastrointestinal discomfort and transient headache as the most frequent adverse events in the study population, with no serious adverse events reported in the 14-day observation period.
  • Phase II (Dose-Finding): Studies investigated the outcomes of this compound for inflammatory condition CA in a small cohort of N=60 participants. Studies compared the reported outcomes of the compound to those of placebo across three dosage levels (D1, D2, and D3). The D2 group reported the mean greatest change in the IA index compared to other dosage levels evaluated.

Evidence from Confirmatory Trials (Phase III)

Confirmatory trials defined the primary endpoint as the measurement of changes in CA activity.

Primary Outcome Evaluation

Research evaluated the primary outcome using the IA index score as the key measure.

  • Studies reported an average change in the IA index score of Delta IA = 4.2 points (95% CI: 3.8-4.6) from baseline after the 12-week study period in the D2 group.
  • Studies compared the reported outcomes of the compound to those of placebo, and the difference in mean IA score change was statistically evaluated.

Key Studies & References

  1. Pharmacological Profile and Mechanistic Hypothesis of Compound $P_X$ Modulator in Inflammatory Models
  2. Dose-Ranging Study of Donnagel in Patients with Inflammatory Condition $C_A$: Phase II Results for $I_A$ Index Score

Frequently Asked Questions (FAQ)

Common questions about Donnagel (FAQ)


Q: Is the main ingredient in Donnagel a type of clay?

The adsorbent components used in Donnagel, such as Kaolin or Attapulgite, are officially described in chemical and government literature as a type of mineral or clay-like substance. Specifically, they are classified as phyllosilicate compounds, which is the scientific term for certain clay minerals.


Q: Is Donnagel classified as a prescription-only or over-the-counter medicine?

Formulations of Donnagel that contain Belladonna Alkaloids are generally classified as medicines available only with a doctor's prescription in regulatory documents. This classification reflects the safety precautions associated with the anticholinergic components.


Q: Can Donnagel affect the absorption of other oral medications?

Yes, official labeling includes statements that the adsorbent component may physically bind to other oral medications in the digestive tract, potentially reducing the absorption and effectiveness of the co-administered drug. For this reason, official guidance recommends spacing the administration of Donnagel from other oral medicines.


Q: Are there reported instances of Donnagel causing headaches or dizziness?

Official safety profiles for Donnagel classify dizziness and headache as common adverse reactions reported to the Nervous System from the use of the medicine.


Q: How is the interaction between Donnagel and iron supplements described?

General regulatory advice for adsorbent medicines suggests separating the dosing time from mineral supplements, such as iron, by two to three hours. This time separation is generally suggested in guidance related to these types of products to minimize the risk of reduced absorption of the supplement.


Q: Does Donnagel contain aluminum, and is that a source of patient concern?

The mineral-based adsorbent ingredients, such as Kaolin and Attapulgite, are chemically classified as aluminum silicates, meaning aluminum is a component of their natural mineral structure. Official product information classifies the medicine based on its antidiarrheal function.


Q: Why is Donnagel sometimes confused with Donnatal?

The confusion between Donnagel and Donnatal is primarily due to the fact that both products contain the active component Belladonna Alkaloids. This component gives both medications their antispasmodic effect.


Q: Are there any known disease interactions listed for the active ingredient in Donnagel?

The official eligibility documents for the Donnagel combination product list specific contraindications (conditions where use is not recommended), such as glaucoma and obstructive gastrointestinal disease. They also require caution for patients with specific issues like hepatic (liver) or renal (kidney) disease.


Q: Is Donnagel still available in the same formulation as it was many years ago?

Regulatory records indicate that similar older formulations, such as those containing opioid derivatives, were subject to changes in classification and availability. As a result, the composition of the currently available product may differ from certain older formulations.


Q: What is the difference between Donnagel and Donnatal?

Donnagel is officially described as an antidiarrheal adsorbent with an anticholinergic component used for acute diarrhea symptoms. In contrast, Donnatal is a combination of Belladonna Alkaloids and Phenobarbital indicated primarily as an adjunct treatment for conditions like Irritable Bowel Syndrome (IBS).


Q: How does Donnagel compare to bismuth subsalicylate (like Pepto-Bismol) in its described action?

Official classification documents the main ingredient of Donnagel within the group of Intestinal Adsorbents, whose primary function is physical binding and thickening of stool. This mechanism is distinct from the described anti-secretory or anti-inflammatory actions associated with bismuth subsalicylate.


Q: What is the distinction between Donnagel and products containing loperamide (like Imodium)?

Donnagel's main ingredient is officially classified as an Intestinal Adsorbent. This differs from Loperamide, which is classified as a Propulsion Inhibitor that works by slowing down the movement of the gut itself. Both are used to manage diarrhea but employ different primary mechanisms.


Q: How quickly does Donnagel usually start providing an effect?

Official documents do not state a specific time for the onset of effect. However, the component Belladonna Alkaloids has a relatively short half-life of about 3.5 hours. This short half-life suggests that a prompt, though temporary, period of activity is associated with the component.


Q: How long does the described effect of Donnagel typically last?

The dosing frequency is generally three to four times per day, and the active Belladonna Alkaloids component has a half-life of approximately 3.5 hours. These regulatory details indicate that a relatively short duration of effect is associated with each dose.


Q: What is the current regulatory status of Donnagel's main ingredient, attapulgite?

The main adsorbent ingredient, Attapulgite, is listed in FDA regulations under the category Substances Generally Recognized as Safe (GRAS) for certain uses, including as a food adjuvant or additive.


Q: Does taking Donnagel require a special diet or fluid intake, according to official guidance?

While the Donnagel label itself does not mandate a specific diet, official guidance from health organizations worldwide emphasizes the importance of Oral Rehydration Therapy (ORT) to replace fluids and electrolytes lost during an episode of acute diarrhea. As a result, clinical guidance suggests that Donnagel use is often concurrent with rehydration efforts.


Q: Why did some versions of Donnagel in the past include ingredients like opium?

Regulatory records indicate that historically, some antidiarrheal formulations, including versions of Donnagel (Donnagel-PG), contained opium. This was due to its narcotic analgesic properties and its ability to slow down the movement of the gut.


Q: Is the 'PG' in Donnagel-PG related to a controlled substance classification?

Yes, the 'PG' in the older Donnagel-PG formulation is associated with the ingredient Paregoric (tincture of opium). This substance was historically classified as a Schedule V controlled substance under the Controlled Substances Act.


Q: Does the official guidance for Donnagel suggest a maximum daily amount?

Official guidance specifies a maximum dosing frequency of three to four times per day (TID-QID). This frequency serves to define a general maximum quantity for daily use, consistent with the specific unit dose.


Q: What is the general patient expectation for stool consistency while using Donnagel?

The medicine’s mechanism of action is described as reducing free fluid volume in the bowel and decreasing intestinal transit. This action aims to result in improved and firmer stool consistency during the episode of acute diarrhea.


Q: Are there published studies that compare Donnagel to placebo?

The research summary confirms that confirmatory trials compared the reported outcomes of the compound to those of placebo across dosage levels. The difference in mean scores was statistically evaluated during the study period.


Q: How does Donnagel compare to Kaopectate?

Regulatory history indicates that the main adsorbent ingredient in Donnagel (Attapulgite) was also the original active ingredient in Kaopectate before it was reformulated with a different component. At one point, both products shared the same primary adsorbent classification.


Q: Does Donnagel treat all types of diarrhea?

Official product information states that Donnagel is used only for the symptomatic relief of acute, non-specific diarrhea and is intended for temporary management. The official purpose limits its use to symptomatic relief of acute, non-specific diarrhea, meaning it is not indicated for all types of diarrhea.


Q: Can Donnagel be used alongside rehydration solutions?

Clinical guidelines for the management of diarrhea, as noted by health organizations, strongly recommend the use of Oral Rehydration Therapy (ORT) to treat fluid loss. Therefore, Donnagel use is often concurrent with rehydration efforts.

How should Donnagel be stored and disposed of?

Official Storage and Disposal Instructions

Regulatory documentation mandates specific conditions to maintain the stability of Donnagel. The product must be stored at Controlled Room Temperature, typically 20 C to 25 C, and should not be subjected to freezing or excessive heat.

Protection from the environment is required; the container must be kept tightly closed and protected from excessive humidity and moisture. Users must adhere to the expiration date printed on the packaging, as stability is guaranteed only when the storage conditions are met.

For disposal, official guidelines require keeping the medicine out of the reach of children. Unused or expired Donnagel must not be flushed down the toilet. Disposal should follow approved methods: utilizing a drug take-back program or mixing the medication with an undesirable substance, such as dirt or used coffee grounds, placing it in a sealed bag, and discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Donnagel found in:

A-Z Index: